Pulmonary hypertension research demonstrates that monocrotaline treatment enhances LPO through upregulation of Toll‐like receptor 4 (TLR4)/NLRP3 expression, while ferrostatin‐1 intervention effectively maintains GPX4 and ferritin heavy chain 1 (FTH1) levels, alleviating pulmonary vascular endothelial cell loss and right ventricular remodeling [206]. This evidence concerns the gene FTH1 and pulmonary hypertension.